All News
EULAR 2024 Rheumatology Roundup (6.21.2024)
Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna
Read Article
Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
https://t.co/vN2VZYGqbE https://t.co/MQ3QCJU4SW
Dr. John Cush RheumNow ( View Tweet)
DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
https://t.co/gKJRygBeq0 https://t.co/2NTNYJLPNZ
Dr. John Cush RheumNow ( View Tweet)
Damage in Childhood Lupus
Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.
https://t.co/wCygK0LGvd https://t.co/tm8LTI28mh
Dr. John Cush RheumNow ( View Tweet)
RA: update for women of child bearing potential (and men!)
Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.
https://t.co/RrkR2V3CI3 https://t.co/CRXUKxUqF2
Dr. John Cush RheumNow ( View Tweet)
Difficult-to-treat Rheumatoid Arthritis: Validation of the EULAR Definition
Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria.
https://t.co/oc3Aj60KsM https://t.co/40FMjbKEHF
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 Daily Recap: Days 1 & 2
Dr. Jack Cush moderates EULAR 2024 RECAP for days 1 & 2 with Drs. Mrinalini Day and Yuz Yusof in Vienna, Austria.
https://t.co/gRMVUXhTxw https://t.co/YV8vjVUCJn
Dr. John Cush RheumNow ( View Tweet)
Rituximab to Treat Systemic Features of Sjogren's
Dr. Yuz Yusof discusses abstract OP0076 presented at Eular 2024 in Vienna, Austria.
https://t.co/9oJNz12cCI https://t.co/bZxpbf3PT9
Dr. John Cush RheumNow ( View Tweet)
Update on Sjogren's disease trials
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease.
https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK
Dr. John Cush RheumNow ( View Tweet)
New Treatments for Systemic Sclerosis
aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z
Dr. John Cush RheumNow ( View Tweet)
Camels and psoriatic arthritis - a new treatment link
https://t.co/0SQt3UPmKu https://t.co/zvwH9iYtxX
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 – Day 4 Report
The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations. Below is a synopsis of the half-day's action.
https://t.co/1lQcu1beOm https://t.co/QHMcFzaG48
Dr. John Cush RheumNow ( View Tweet)
We've Got to Talk about CAR T cells
Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.
https://t.co/mrr5MWxeJz https://t.co/0FMLaAxaWV
Dr. John Cush RheumNow ( View Tweet)
Select your GCA Therapy
Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/TPBeU7KaEq https://t.co/09uEzM3Kkd
Dr. John Cush RheumNow ( View Tweet)
Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.
https://t.co/Nc0XymI24l https://t.co/69qdLh63ct
Dr. John Cush RheumNow ( View Tweet)
Giant Cell Arteritis and Polymyalgia Rheumatica Update
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
https://t.co/0V9Sle0GMU https://t.co/ixeT8L562C
Dr. John Cush RheumNow ( View Tweet)
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
https://t.co/mv9DeZ9cez https://t.co/1OpT3MomO8
Dr. John Cush RheumNow ( View Tweet)
Update on low-dose glucocorticoids in SLE
GC have been the mainstay of treatment in SLE for nearly 75 yrs. GC induce anti-inflammatory effects, quickly relieve symptoms, and reduce mortality in life-threatening flares through various actions.
https://t.co/uEtWftvwEz https://t.co/nJlpELMj5W
Dr. John Cush RheumNow ( View Tweet)
Achieving drug-free remission in axSpA
In early axSpA, over 60% achieved sustained inactive disease. Male, non-smokers, low BASDAI scores had higher remission rates. Drug-free remission remains challenging.
https://t.co/Yv8a8C1hc9 https://t.co/JaYvfGry4P
Dr. John Cush RheumNow ( View Tweet)
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa
Retrospective study in French THIN database
Diagnostic delay remains common
Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain
#EULAR2024 @DrMiniDey https://t.co/egwDL1XjSw
Dr. John Cush RheumNow ( View Tweet)